http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Stress Determination in Epitaxial Lead Titanate Films by Asymmetric X-ray Diffraction Method
Uchida, Hiroshi,Kiguchi, Takanori,Wakiya, Naoki,Shinozaki, Kazuo,Mizutani, Nobuyasu The Korean Ceramic Society 2000 The Korean journal of ceramics Vol.6 No.4
Residual stresses in epitaxial films were measured by X-ray diffraction method. Lattice strains of the (hkl) planes measured along particular Ψ-angles were converted to the in-plane stress according to the equation of stress-strain tensor conversion. Residual tensile stresses were observed in epitaxial PbTiO$_3$ films deposited on (100) SrTiO$_3$ substrate. Tensile stresses approximately 0.9 GPa were measured in Pb-rich films, while it increased to approximately 2.0 GPa with the decreasing of Pb content in the case of Pb-poor films, which ascribed to the formation of lead and oxygen vacancies (expressed as x in Pb$_1-x$TiO$_3-x$).
Ohmachi, Ken,Niitsu, Nozomi,Uchida, Toshiki,Kim, Seok Jin,Ando, Kiyoshi,Takahashi, Naoki,Takahashi, Naoto,Uike, Naokuni,Eom, Hyeon Seok,Chae, Yee Soo,Terauchi, Takashi,Tateishi, Ukihide,Tatsumi, Mitsu American Society for Clinical Oncology 2013 Journal of clinical oncology Vol.31 No.17
<P><B>Purpose</B></P><P>Effective and less aggressive therapies are required for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for or have undergone autologous stem-cell transplantation (ASCT). The present phase II study assessed the efficacy and safety of bendamustine plus rituximab (BR) in this population.</P><P><B>Patients and Methods</B></P><P>Patients with relapsed or refractory DLBCL treated with one to three prior chemotherapy regimens received rituximab 375 mg/m<SUP>2</SUP> intravenous (IV) infusion on day 1 and bendamustine 120 mg/m<SUP>2</SUP> by IV infusion on days 2 and 3 of each 21-day cycle for up to six cycles. The primary end point was overall response rate (ORR), and the secondary end points were complete response (CR) rate, progression-free survival (PFS), and safety.</P><P><B>Results</B></P><P>Sixty-three patients were enrolled, and 59 received BR. The median age was 67 years (range, 36 to 75 years), and 62.7% of patients were 65 years of age or older. Fifty-seven patients (96.6%) were previously treated with rituximab-containing chemotherapy. The ORR was 62.7% (95% CI, 49.1% to 75.0%), with a CR rate of 37.3% (95% CI, 25.0% to 50.9%). The ORRs were comparable between patients ≥ 65 years of age and less than 65 years (62.2% and 63.6%, respectively). The median PFS was 6.7 months (95% CI, 3.6 to 13.7 months). The most frequently observed grade 3 or 4 adverse events were hematologic: lymphopenia (78.0%), neutropenia (76.3%), leukopenia (72.9%), CD4 lymphopenia (66.1%), and thrombocytopenia (22.0%).</P><P><B>Conclusion</B></P><P>BR is a promising salvage regimen for patients with relapsed or refractory DLBCL after rituximab-containing chemotherapy, warranting further investigation.</P>
Developmental and age-related changes of peptidylarginine deiminase 2 in the mouse brain
Shimada, Nobuko,Handa, Setsuko,Uchida, Yoshiaki,Fukuda, Mitsugu,Maruyama, Naoki,Asaga, Hiroaki,Choi, Eun-Kyoung,Lee, Jaewon,Ishigami, Akihito Wiley Subscription Services, Inc., A Wiley Company 2010 Journal of neuroscience research Vol.88 No.4
<P>Peptidylarginine deiminases (PADs) are a group of posttranslational modification enzymes that citrullinate (deiminate) protein arginine residues in a Ca<SUP>2+</SUP>-dependent manner. Enzymatic citrullination abolishes positive charges of native protein molecules, inevitably causing significant alterations in their structure and functions. Among the five isoforms of PADs, PAD2 and PAD4 are proved occupants of the central nervous system (CNS), and especially PAD2 is a main PAD enzyme expressed in the CNS. We previously reported that abnormal protein citrullination by PAD2 has been closely associated with the pathogenesis of neurodegenerative disorders such as Alzheimer's disease and prion disease. Protein citrullination in these patients is thought to play a role during the initiation and/or progression of disease. However, the contribution of changes in PAD2 levels, and consequent citrullination, during developmental and aging processes remained unclear. Therefore, we used quantitative real-time RT-PCR, Western blot analysis, and immunohistochemical methods to measure PAD2 expression and localization in the brain during those processes. PAD2 mRNA expression was detected in the brains of mice as early as embryonic day 15, and its expression in cerebral cortex, hippocampus, and cerebellum increased significantly as the animals aged from 3 to 30 months old. No citrullinated proteins were detected during that period. Moreover, we found here, for the first time, that PAD2 localized specifically in the neuronal cells of the cerebral cortex and Purkinje cells of the cerebellum. These findings indicate that, despite PAD2's normally inactive status, it becomes active and citrullinates cellular proteins, but only when the intracellular Ca<SUP>2+</SUP> balance is upset during neurodegenerative changes. © 2009 Wiley-Liss, Inc.</P>
Masaru Tateno,Saya Kikuchi,Kumi Uehara,Kyoko Fukita,Naoki Uchida,Ryuji Sasaki,Toshikazu Saito 대한신경정신의학회 2011 PSYCHIATRY INVESTIGATION Vol.8 No.1
The concept of pervasive developmental disorders (PDD) and autism spectrum disorders (ASD) closely resemble each other. Both ICD-10 and DSM-IV use the term PDD. The authors surveyed the perception of PDD/ASD and attitudes toward terminology. The subjects of this study were 205 medical/social-welfare professionals working in fields relating to developmental disorders. Questionnaires were mailed to site investigators at the collaborating institutes. With regard to what the scope of ASD and PDD encompasses, the answers were almost equally divided among three views: ASD and PDD are the same, PDD is wider in scope and ASD is wider. The terms PDD and autism were used in slightly different ways depended upon the situation. Our results demonstrate that the parameters of PDD and ASD are unclear and that the terms related to PDD/ASD are often used differently. Further studies are required to develop more clear and reliable diagnostic criteria for PDD.
Ryo Harada,Hironari Kato,Soichiro Fushimi,Hirofumi Inoue,Daisuke Uchida,Yutaka Akimoto,Takeshi Tomoda,Kazuyuki Matsumoto,Yasuhiro Noma,Naoki Yamamoto,Shigeru Horiguchi,Koichiro Tsutsumi,Hiroyuki Okada 대한소화기내시경학회 2019 Clinical Endoscopy Vol.52 No.4
Background/Aims: We applied a back light system (BLS) with a magnifying glass to improve the ability to assess the adequacy ofspecimen sampling using endosonography. We conducted this study to evaluate the effcacy of the BLS in sampling of specimens byendoscopic ultrasound-guided fine needle aspiration of solid pancreatic masses. Methods: This was a prospective, randomized, crossover, single-center clinical trial. An endosonographer evaluated adequacy on grossvisual inspection and identified whitish specimen sampling sites with and without the BLS according to a randomization sequence inthe first and second passes with a 25-G needle. On cytological evaluation, the presence of well-defined pancreatic ductal epithelium wasevaluated by a cytopathologist who was blinded to any clinical information. Results: A total of 80 consecutive patients were eligible during the study period. Adequacy was observed for 52 specimens (65%) withthe BLS and 54 (68%) without the BLS (p=0.88). In assessment of specimen adequacy on gross examination, only fair agreement wasobserved both with and without BLS (kappa score 0.40 and 0.29, respectively). Conclusions: The BLS did not influence the ability to identify specimen sampling sites or reliable assessment of specimen site adequacyusing gross visual inspection.